TU + NET-EN
Testosterone Undecanoate (TU) + Norethisterone Enanthate (NET-EN)
- User: Male
- Hormonal: Hormonal
-
Delivery type:
- Injectable
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): Bayer, CONRAD, WHO
Details
- API: Testosterone Undecanoate, Norethisterone Enanthate
- Target: Progesterone Receptor, Androgen Receptor
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Undetermined
- Regimen: 1 Injection/8 Weeks
- MPT: Not Potential MPT
Product Status
Development ended after WHO trial halt
History
See linked literature below for information on safety and biocompatibility
A global Phase IIb clinical trial was discontinued in April 2011 after a WHO review panel determined that AEs -largely concerningly-high prevalence of mild-to-moderate mood disorders- would outweigh the potential benefits to male participants.